REVA Medical

What REVA Medical does

REVA Medical is a medical device company specializing in bioresorbable polymer technologies for vascular applications. The company develops implantable scaffolds designed to restore blood flow and then resorb into the body over time, targeting peripheral artery disease — specifically below-the-knee (BTK) critical limb-threatening ischemia — and coronary artery disease. REVA serves interventional cardiologists and vascular surgeons at hospitals in European markets where its products hold CE Mark approval; the United States is a future market entry opportunity contingent on FDA approval.

The company's commercial portfolio centers on two bioresorbable scaffolds manufactured from Tyrocore, REVA's proprietary tyrosine-derived polycarbonate polymer. Tyrocore provides approximately 100-110 MPa ultimate tensile strength (about twice that of PLLA), 120-200% elongation at break (roughly 10x more ductile than PLLA), and inherent radiopacity that eliminates the need for contrast agent additives. MOTIV is a sirolimus-eluting scaffold for BTK peripheral artery disease and is the first bioresorbable scaffold to receive CE Mark for that indication; it also holds FDA Breakthrough Device Designation. Fantom Encore is a third-generation sirolimus-eluting scaffold for coronary artery disease, marketed as having the thinnest struts of any commercially available CE Mark bioresorbable scaffold. The Tyrocore platform also underpins TyroSphere, bioresorbable embolic microspheres for hypervascular tumor treatment, currently listed as a pipeline product. Over 20+ years, REVA has developed 19 distinct polymer families.

REVA generates revenue through one-time hardware sales of its scaffolds to hospitals and healthcare providers. Commercialization is currently concentrated in select European countries via direct hospital sales and through HealthLink Europe BV as a distribution partner. Pricing is not publicly disclosed and is typically negotiated on a quote basis. The company emerged from bankruptcy in August 2022 with a $45 million funding round led by BioStar Capital and is headquartered in San Diego, California with 51-100 employees.

Name

REVA Medical

Legal name

REVA Medical, LLC.

Website

https://revamedical.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

REVA Medical is a medical device company developing bioresorbable polymer-based vascular scaffolds (Tyrocore polymer platform), serving interventional cardiologists treating below-the-knee peripheral and coronary artery disease in select European markets.

Ownership category

akta.pro rank

Product category

Interventional Vascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industries

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA), Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)

Keywords

• Bioresorbable scaffolds
• Vascular medical devices
• Peripheral artery implants
• Coronary scaffolds
• Bioresorbable polymers

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: REVA generates revenue through the sale of bioresorbable vascular scaffolds and related medical devices. Fantom Encore is currently available for sale in select European countries. Revenue is generated on a one-time product transaction basis as hospitals and healthcare providers purchase devices for interventional procedures.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

REVA Medical develops and manufactures bioresorbable vascular scaffolds and embolic microspheres using its proprietary Tyrocore polymer. Its commercial and clinical products include MOTIV, a sirolimus-eluting bioresorbable scaffold for below-the-knee peripheral artery disease (CE Marked, FDA Breakthrough Designation), and Fantom Encore, a third-generation bioresorbable scaffold for coronary artery disease. The company is also developing TyroSphere bioresorbable embolic beads for hypervascular tumors.

Product overview

REVA Medical is a medical device company specializing in bioresorbable polymer technologies for vascular applications. The product portfolio centers on two main bioresorbable scaffolds—MOTIV (for peripheral artery disease below-the-knee) and Fantom Encore (for coronary artery disease)—both manufactured using the proprietary Tyrocore tyrosine-derived polycarbonate polymer. The company is also developing TyroSphere, bioresorbable embolic beads for tumor treatment. All products are designed to resorb from the body over time, improving long-term patient outcomes compared to permanent metallic implants.

Differentiator

Problem solved

Functional benefit

Brands

• Tyrocore: Proprietary tyrosine-derived polycarbonate polymer invented specifically for bioresorbable scaffolds.
• TyroSphere
• Fantom Encore
• MOTIV

Products and services

• MOTIV Bioresorbable Scaffold

Quantifiable outcome

• MOTIV achieved 70% patency at 12 months vs 48% for balloon angioplasty (22% absolute improvement)
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• HealthLink Europe BVcoreChannel Partner/ Reseller/ DistributorEuropean distribution and order fulfillment partner for REVA Medical products. Handles order placement and customer inquiries for European markets. Located in the Netherlands with phone (+31 73 303 2559) and fax (+31 73 369 0551) contact information.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Abbott: Abbott developed Absorb GT1, the most prominent bioresorbable coronary scaffold, before withdrawing it in 2017 over safety concerns. As the dominant interventional cardiology player, Abbott remains the primary incumbent REVA competes against in vascular scaffolds, with vastly greater resources and hospital penetration.
• Medtronic: Medtronic is a global leader in interventional cardiology with durable metallic drug-eluting stents (Resolute, Onyx families) and peripheral vascular devices. As an incumbent with deep hospital relationships, it competes directly for the same interventional cardiology and BTK procedure volumes.
• Biotronik: Biotronik developed the Magmaris magnesium-based bioresorbable scaffold (DREAMS) for coronary use and has a broad peripheral vascular intervention portfolio. As an incumbent with BRS experience, Biotronik competes across both coronary and peripheral vascular categories.
• Boston Scientific: Boston Scientific is a major interventional cardiology and peripheral vascular device manufacturer with durable metallic drug-eluting stents. It is one of the entrenched players whose products REVA's bioresorbable scaffolds aim to displace in coronary and peripheral indications.
• Terumo: Terumo has a substantial interventional systems business with drug-eluting stents and peripheral vascular devices. As a large diversified player with vascular intervention products, it competes for hospital contracts and procedure volumes.

Direct peers

• Elixir Medical: Elixir Medical develops bioresorbable scaffold systems (DESolve and MeVO) for coronary artery disease. It is the closest direct competitor to REVA in the bioresorbable scaffold category, pursuing the same clinical and regulatory pathway with similar technology philosophy.
• Meril Life Sciences: Meril Life Sciences developed MeRes100, a bioresorbable coronary scaffold that has received regulatory approvals in India and other markets. As a competing BRS developer focused on bioresorbable technology, Meril is a direct peer in the same product category.
• Amaranth Medical: Amaranth Medical developed the APTITUDE bioresorbable scaffold system for coronary artery disease. As a bioresorbable scaffold developer pursuing similar regulatory and commercial milestones, it is a direct peer in the BRS category.

Emerging players

• Penumbra: Penumbra focuses on vascular thrombectomy and embolization devices, with overlap in the peripheral vascular intervention space and in embolic technologies (relevant to REVA's TyroSphere embolic bead program).
• Sirtex Medical: Sirtex develops SIR-Spheres, a leading radioembolization (embolic bead) product for liver tumors. As a company in the oncology embolization space, it is a relevant peer for REVA's TyroSphere embolic bead program.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/revamedicalinc
• LinkedInlinkedin.com/company/reva-medical-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REVA Medical